Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Vanda Pharmaceuticals (VNDA) over the last 13 years, with Q3 2025 value amounting to $3.0 million.

  • Vanda Pharmaceuticals' Cost of Revenue rose 1579.77% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year decrease of 314.35%. This contributed to the annual value of $11.3 million for FY2024, which is 2353.34% down from last year.
  • According to the latest figures from Q3 2025, Vanda Pharmaceuticals' Cost of Revenue is $3.0 million, which was up 1579.77% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Cost of Revenue ranged from a high of $6.8 million in Q3 2021 and a low of $2.6 million during Q3 2024
  • For the 5-year period, Vanda Pharmaceuticals' Cost of Revenue averaged around $4.5 million, with its median value being $3.5 million (2025).
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 1580.56% in 2021, then crashed by 5153.48% in 2023.
  • Vanda Pharmaceuticals' Cost of Revenue (Quarter) stood at $6.2 million in 2021, then grew by 0.03% to $6.2 million in 2022, then tumbled by 44.53% to $3.5 million in 2023, then decreased by 25.14% to $2.6 million in 2024, then grew by 14.05% to $3.0 million in 2025.
  • Its Cost of Revenue was $3.0 million in Q3 2025, compared to $2.7 million in Q2 2025 and $3.5 million in Q1 2025.